Response Pharmaceuticals
Developer an intestinal microsomal triglyceride transfer protein inhibitor designed to treat the metabolic side effects of antipsychotic drugs. The company develops treatments for post-prandial trigly...
Valuation
$0
Share Price
N/A
Total Raised
$11.9M
Last Round
N/A